Skip to content

Clarify Pharma PLC - Notice of AGM

Announcement provided by

Clarify Pharma PLC · PSYC

05/05/2022 07:00

Clarify Pharma PLC - Notice of AGM
RNS Number : 3351K
Clarify Pharma PLC
05 May 2022

Press Release


05 May 2022



Clarify Pharma PLC

("Clarify Pharma" or "the Company")


Notice of Annual General Meeting


Clarify Pharma (AQSE: PSYC), an investment vehicle specialising in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic-based substances, announces that it will hold its Annual General Meeting ('AGM') at 11:00am on Monday 30th May 2022 at the offices of Fladgate LLP, 16 Great Queen Street, London, England, WC2B 5DG.

Further details of the arrangements for this year's AGM are set out in the Notice of AGM, which together with the Form of Proxy, will be posted to shareholders today. The Notice of AGM will shortly also be available on the Company's website.

The directors of Clarify Pharma plc accept responsibility for this announcement.

For further information please contact:

Clarify Pharma

Jon Bixby

Executive Chairman

via Tancredi +44 207 887 7633




First Sentinel

Corporate Adviser

Brian Stockbridge


+44 7876 888 011

Tennyson Securities

Corporate Broker

Peter Krens

+44 207 186 9030

Tancredi Intelligent Communication

Media Relations

Catrina Daly

Emma Hodges

Salamander Davoudi


+44 7727 153 868

+44 7861 995 628

+44 7957 549 906



About Clarify Pharma PLC:


Listed on the Aquis Stock Exchange in London, Clarify Pharma is an investment vehicle focusing on investing in biotech and life sciences companies seeking to prove the safety and efficacy of psychedelic based substances. The Company looks to identify investment opportunities in the life sciences sector within the UK, Canada and other growing markets, with the objective of generating long-term capital growth and building investments in an R&D pipeline of companies which are discovering, developing, or deploying safe and evidence-based psychedelic inspired medicines and experiential therapies that alleviate mental health problems and enhance wellbeing. The Company's Directors have an established track record, experience and networks in the psychedelic, cannabinoid and media industries, to drive value creation.




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

View more ...

PSYC announcementsAll announcements


  • About
  • News
  • Investor Relations
  • Contact
  • Careers

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal